Company Overview and News

 
ResApp shares down on study results

2018-04-10 businessnews.com.au
Shares in medical tech company ResApp Health slumped today after the company released positive testing results, following a solid increase in the share price leading up to the announcement.
Upvote Downvote

 
ResApp Health set to begin U.S. study of its app to diagnose respiratory diseases

2018-01-11 proactiveinvestors.com.au
ResApp Health Ltd (ASX:RAP) has secured its third institutional review board (IRB) approval in the U.S. for a study that will evaluate the efficacy of the ResAppDx smartphone application.
Upvote Downvote

 
ASX rises for fourth day to fresh decade high

2018-01-08 theage.com.au
Australian shares rose for a fourth straight session on Monday to a fresh decade-high level on gains in healthcare and financials stocks.
Upvote Downvote

 
ASX rises for fourth day to fresh decade high

2018-01-08 smh.com.au
Australian shares rose for a fourth straight session on Monday to a fresh decade-high level on gains in healthcare and financials stocks.
Upvote Downvote

 
Resapp Health embarking on new study to evaluate efficacy

2018-01-08 proactiveinvestors.com.au
Resapp Health Ltd (ASX:RAP), a developer of smartphone applications for the diagnosis and management of respiratory disease, has enrolled the first patient in its SMARTCOUGH-C-2 study in the United States.
Upvote Downvote

 
ResApp Health director provides share support through on-market buying

2017-10-06 proactiveinvestors.com.au
ResApp Health Ltd's (ASX:RAP) executive director, Brian Leedman, has provided support for the company's valuation through the purchase of 876,000 shares on-market this week for a consideration of $64,500.
Upvote Downvote

 
ResApp Health's shares are being snapped up

2017-09-22 proactiveinvestors.com.au
ResApp Health Ltd (ASX:RAP) has received a notice of initial substantial shareholder from Ian Francis Reynolds, who now holds circa 37 million shares for a 5.6% stake.
Upvote Downvote

 
Resapp Health to restart respiratory app study after enhancing its technology

2017-09-14 proactiveinvestors.com.au
Resapp Health Ltd (ASX:RAP) is planning to restart the U.S. paediatric clinical study of its “ResAppDx” app to detect respiratory diseases, this U.S. winter.
Upvote Downvote

 
ResApp Health director buys 1,000,000 shares on-market

2017-08-10 proactiveinvestors.com.au
ResApp Health Ltd's (ASX:RAP) non-executive director, Chris Ntoumenopoulos, has thrown his support behind the company by purchasing one million shares on-market for a consideration of $72,821.92.
Upvote Downvote

 
ResApp Health is the ASX Volume Leader as investor call breathes in new life

2017-08-10 proactiveinvestors.com.au
ResApp Health Ltd (ASX:RAP) shares have soared in afternoon trading, following a massive sell-off yesterday, after the results preliminary top-line results from the SMARTCOUGH-C Study.
Upvote Downvote

 
ResApp crashes on study results

2017-08-09 businessnews.com.au
Shares in medical tech company ResApp Health plummeted 77 per cent today on disappointing results of a clinical study on its ResAppDx technology.
Upvote Downvote

 
ResApp, Atlas Iron and ZipTel top ASX Volume Leaders, but head in different directions

2017-08-09 proactiveinvestors.com.au
There has been some frantic trading in the small caps by mid-session, with high volume not indicating a valuation direction.
Upvote Downvote

 
ResApp Health the leading ASX % Faller in morning trade on big volume

2017-08-09 proactiveinvestors.com.au
ResApp Health Ltd's (ASX:RAP) shares have plunged 76% to $0.074 in the first 90 minutes of trade following the company reporting preliminary top-line results from the SMARTCOUGH-C Study.
Upvote Downvote

 
ResApp Health's shares in pre-open pending partnership update

2017-05-08 proactiveinvestors.com.au
ResApp Health (ASX:RAP) has been granted a trading halt by the ASX, pending an update on the company’s partnership with a humanitarian organisation.
Upvote Downvote

 
ResApp Health expands study of app to diagnose pneumonia

2017-04-19 proactiveinvestors.com.au
ResApp Health (ASX:RAP) is expanding its study to evaluate the efficacy of the ResAppDx app for the diagnosis of childhood pneumonia and other respiratory conditions.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...